Reduction in plasminogen activator inhibitor-1 (PAI-1) with omega-3 polyunsaturated fatty acid (PUFA) intake

Am Heart J. 1988 Nov;116(5 Pt 1):1201-6. doi: 10.1016/0002-8703(88)90440-1.

Abstract

Activity of plasminogen activator inhibitor-1 (PAI-1) in human blood correlates with thrombotic tendency and with serum triglyceride concentrations. Since intake of fish-derived omega-3 polyunsaturated fatty acids (PUFA) decreases serum triglycerides, we examined the effects of omega-3 PUFA maximum eicosapentaenoic acid (Max EPA) intake on PAI-1 levels in eight patients with coronary artery disease and in four normal subjects. After 4 weeks of Max-EPA intake by coronary artery disease patients, serum triglyceride concentrations and PAI-1 levels decreased 43 +/- 8% and 21 +/- 5%, respectively (both p less than or equal to 0.01) without any change in tissue plasminogen activator (TPA) levels. No changes were noted at 1 week of Max EPA intake in normal subjects, but at 3 weeks serum triglyceride concentrations and PAI-1 levels decreased 32 +/- 13% and 22 +/- 4%, respectively (p less than or equal to 0.01) without any change in tissue plasminogen activator (TPA) levels. No changes were noted at 1 week of Max EPA intake in normal subjects, but at 3 weeks serum triglyceride concentrations and PAI-1 levels decreased 32 +/- 13% and 22 +/- 4%, respectively (p less than or equal to 0.02) without change in TPA. The magnitude of reduction in triglycerides was dependent on the initial serum concentration (r = 0.68, p less than or equal to 0.01). In addition, decrease in PAI-1 levels correlated with reduction in serum triglycerides (r = 0.79, p less than or equal to 0.01). This study shows that omega-3 PUFA intake reduces PAI-1 levels without change in TPA antigen. These observations may relate to decrease in thrombotic activity upon consumption of large amounts of fish or fish-derived products.

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Cholesterol / blood
  • Coronary Disease / blood
  • Coronary Disease / diet therapy*
  • Docosahexaenoic Acids*
  • Double-Blind Method
  • Drug Combinations
  • Eicosapentaenoic Acid*
  • Fatty Acids, Unsaturated / therapeutic use*
  • Fish Oils / therapeutic use*
  • Glycoproteins / blood*
  • Humans
  • Male
  • Middle Aged
  • Plasminogen Activators / antagonists & inhibitors*
  • Plasminogen Inactivators*
  • Triglycerides / blood

Substances

  • Drug Combinations
  • Fatty Acids, Unsaturated
  • Fish Oils
  • Glycoproteins
  • Maxepa
  • Plasminogen Inactivators
  • Triglycerides
  • Docosahexaenoic Acids
  • Cholesterol
  • Eicosapentaenoic Acid
  • Plasminogen Activators